Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
Identifieur interne : 002A67 ( Main/Exploration ); précédent : 002A66; suivant : 002A68Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
Auteurs : Koji Ishii [Japon] ; Hideki Hasegawa ; Noriyo Nagata ; Yasushi Ami ; Shuetsu Fukushi ; Fumihiro Taguchi ; Yasuko Tsunetsugu-YokotaSource :
- Microbiology and immunology [ 0385-5600 ] ; 2009.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps monoclonaux (immunologie), Chimiokine CCL2 (analyse), Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (immunologie), Interleukine-6 (analyse), Modèles animaux de maladie humaine, Poids du corps, Protéines de l'enveloppe virale (immunologie), Réplication virale, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Tests de neutralisation, Vaccins antiviraux (immunologie), Vaccins inactivés, Virus du SRAS (immunologie), Virus du SRAS (physiologie).
- MESH :
- analyse : Chimiokine CCL2, Interleukine-6.
- immunologie : Anticorps antiviraux, Anticorps monoclonaux, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- physiologie : Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Glycoprotéine de spicule des coronavirus, Modèles animaux de maladie humaine, Poids du corps, Réplication virale, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Tests de neutralisation, Vaccins inactivés.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Viral (immunology), Body Weight, Chemokine CCL2 (analysis), Disease Models, Animal, Interleukin-6 (analysis), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Neutralization Tests, SARS Virus (immunology), SARS Virus (physiology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Vaccines, Inactivated, Viral Envelope Proteins (immunology), Viral Vaccines (immunology), Virus Replication.
- MESH :
- chemical , analysis : Chemokine CCL2, Interleukin-6.
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Viral, Membrane Glycoproteins, Viral Envelope Proteins, Viral Vaccines.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Body Weight, Disease Models, Animal, Mice, Mice, Inbred BALB C, Neutralization Tests, Spike Glycoprotein, Coronavirus, Vaccines, Inactivated, Virus Replication.
Abstract
We evaluated the efficacy of three SARS vaccine candidates in a murine SARS model utilizing low-virulence Pp and SARS-CoV coinfection. Vaccinated mice were protected from severe respiratory disease in parallel with a low virus titer in the lungs and a high neutralizing antibody titer in the plasma. Importantly, the administration of spike protein-specific neutralizing monoclonal antibody protected mice from the disease, indicating that the neutralization is sufficient for protection. Moreover, a high level of IL-6 and MCP-1 production, but not other 18 cytokines tested, on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity, suggesting the importance of these cytokines in the lung pathogenicity of SARS-CoV infection.
DOI: 10.1111/j.1348-0421.2008.00097.x
PubMed: 19291090
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001942
- to stream PubMed, to step Curation: 001942
- to stream PubMed, to step Checkpoint: 001830
- to stream Ncbi, to step Merge: 001E73
- to stream Ncbi, to step Curation: 001E73
- to stream Ncbi, to step Checkpoint: 001E73
- to stream Main, to step Merge: 002B14
- to stream Main, to step Curation: 002A67
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.</title><author><name sortKey="Ishii, Koji" sort="Ishii, Koji" uniqKey="Ishii K" first="Koji" last="Ishii">Koji Ishii</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name></author><author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name></author><author><name sortKey="Ami, Yasushi" sort="Ami, Yasushi" uniqKey="Ami Y" first="Yasushi" last="Ami">Yasushi Ami</name></author><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name></author><author><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19291090</idno><idno type="pmid">19291090</idno><idno type="doi">10.1111/j.1348-0421.2008.00097.x</idno><idno type="wicri:Area/PubMed/Corpus">001942</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001942</idno><idno type="wicri:Area/PubMed/Curation">001942</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001942</idno><idno type="wicri:Area/PubMed/Checkpoint">001830</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001830</idno><idno type="wicri:Area/Ncbi/Merge">001E73</idno><idno type="wicri:Area/Ncbi/Curation">001E73</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E73</idno><idno type="wicri:doubleKey">0385-5600:2009:Ishii K:neutralizing:antibody:against</idno><idno type="wicri:Area/Main/Merge">002B14</idno><idno type="wicri:Area/Main/Curation">002A67</idno><idno type="wicri:Area/Main/Exploration">002A67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.</title><author><name sortKey="Ishii, Koji" sort="Ishii, Koji" uniqKey="Ishii K" first="Koji" last="Ishii">Koji Ishii</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name></author><author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name></author><author><name sortKey="Ami, Yasushi" sort="Ami, Yasushi" uniqKey="Ami Y" first="Yasushi" last="Ami">Yasushi Ami</name></author><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name></author><author><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name></author></analytic><series><title level="j">Microbiology and immunology</title><idno type="ISSN">0385-5600</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Viral (immunology)</term><term>Body Weight</term><term>Chemokine CCL2 (analysis)</term><term>Disease Models, Animal</term><term>Interleukin-6 (analysis)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>SARS Virus (immunology)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Inactivated</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (immunology)</term><term>Virus Replication</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps monoclonaux (immunologie)</term><term>Chimiokine CCL2 (analyse)</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (immunologie)</term><term>Interleukine-6 (analyse)</term><term>Modèles animaux de maladie humaine</term><term>Poids du corps</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Réplication virale</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Tests de neutralisation</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins inactivés</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Chemokine CCL2</term><term>Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Chimiokine CCL2</term><term>Interleukine-6</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Body Weight</term><term>Disease Models, Animal</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Inactivated</term><term>Virus Replication</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Glycoprotéine de spicule des coronavirus</term><term>Modèles animaux de maladie humaine</term><term>Poids du corps</term><term>Réplication virale</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term><term>Vaccins inactivés</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We evaluated the efficacy of three SARS vaccine candidates in a murine SARS model utilizing low-virulence Pp and SARS-CoV coinfection. Vaccinated mice were protected from severe respiratory disease in parallel with a low virus titer in the lungs and a high neutralizing antibody titer in the plasma. Importantly, the administration of spike protein-specific neutralizing monoclonal antibody protected mice from the disease, indicating that the neutralization is sufficient for protection. Moreover, a high level of IL-6 and MCP-1 production, but not other 18 cytokines tested, on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity, suggesting the importance of these cytokines in the lung pathogenicity of SARS-CoV infection.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><noCountry><name sortKey="Ami, Yasushi" sort="Ami, Yasushi" uniqKey="Ami Y" first="Yasushi" last="Ami">Yasushi Ami</name><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name></noCountry><country name="Japon"><region name="Région de Kantō"><name sortKey="Ishii, Koji" sort="Ishii, Koji" uniqKey="Ishii K" first="Koji" last="Ishii">Koji Ishii</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19291090
|texte= Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19291090" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |